New York State Common Retirement Fund Has $3.43 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

New York State Common Retirement Fund grew its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 54,604 shares of the company’s stock after acquiring an additional 1,170 shares during the quarter. New York State Common Retirement Fund owned 0.06% of Vaxcyte worth $3,429,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Rathbones Group PLC acquired a new position in shares of Vaxcyte during the 3rd quarter worth approximately $221,000. Keybank National Association OH increased its stake in Vaxcyte by 12.9% during the 3rd quarter. Keybank National Association OH now owns 4,565 shares of the company’s stock worth $233,000 after acquiring an additional 522 shares during the period. Daiwa Securities Group Inc. raised its holdings in Vaxcyte by 1,122.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 3,886 shares of the company’s stock valued at $244,000 after acquiring an additional 3,568 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Vaxcyte by 1,122.6% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,575 shares of the company’s stock valued at $284,000 after acquiring an additional 5,119 shares in the last quarter. Finally, Avior Wealth Management LLC lifted its position in shares of Vaxcyte by 33.9% during the 4th quarter. Avior Wealth Management LLC now owns 4,670 shares of the company’s stock valued at $293,000 after acquiring an additional 1,183 shares during the period. 96.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Friday, January 12th. Needham & Company LLC restated a “buy” rating and set a $95.00 price objective on shares of Vaxcyte in a research report on Wednesday, April 10th. Four equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte currently has a consensus rating of “Buy” and a consensus target price of $78.50.

Insider Buying and Selling at Vaxcyte

In related news, COO Jim Wassil sold 3,000 shares of Vaxcyte stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $73.71, for a total value of $221,130.00. Following the transaction, the chief operating officer now directly owns 220,852 shares of the company’s stock, valued at $16,279,000.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $61.92, for a total value of $928,800.00. Following the transaction, the chief executive officer now directly owns 477,847 shares of the company’s stock, valued at approximately $29,588,286.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jim Wassil sold 3,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $73.71, for a total value of $221,130.00. Following the sale, the chief operating officer now owns 220,852 shares in the company, valued at approximately $16,279,000.92. The disclosure for this sale can be found here. In the last quarter, insiders have sold 63,294 shares of company stock worth $4,254,105. Insiders own 3.60% of the company’s stock.

Vaxcyte Stock Up 2.2 %

Shares of PCVX opened at $65.96 on Monday. The stock has a market cap of $7.15 billion, a PE ratio of -15.97 and a beta of 0.94. Vaxcyte, Inc. has a 12-month low of $44.20 and a 12-month high of $82.04. The business has a 50-day simple moving average of $66.83 and a two-hundred day simple moving average of $62.13.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same quarter last year, the company posted ($0.73) EPS. On average, equities research analysts expect that Vaxcyte, Inc. will post -4.18 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.